|
| Press Releases |
|
 |
|
| Thursday, March 12, 2026 |
|
|
OrbusNeich Achieves Record-breaking Revenue, Sales Volume and Gross Profit in FY2025, Net Profit Rises to US$42 million, Final Dividend Increases by 20% to HK12 Cents per Share |
| OrbusNeich Medical Group Holdings Limited ('OrbusNeich' or the 'Group'; stock code: 6929), a multinational medical device company specializing in interventional devices for percutaneous coronary intervention ('PCI') and percutaneous transluminal angioplasty ('PTA') procedures, today announced its annual results for the year ended December 31, 2025 ('FY2025' or the 'Year'). more info >> |
|
| Friday, August 15, 2025 |
|
|
OrbusNeich Records Growth in 2025 Interim Results, Revenue and Net Profit Reach US$83.6 Million and US$19.8 Million Respectively |
| OrbusNeich Medical Group Holdings Limited ('OrbusNeich' or the 'Group'; stock code: 6929), a multinational medical device company specializing in interventional devices for percutaneous coronary intervention ('PCI') and percutaneous transluminal angioplasty ('PTA') procedures, today announced its interim results for the six months ended June 30, 2025 (the 'Period'), reporting growth in both revenue and net profit despite an uncertain macroeconomic landscape. more info >> |
|
| Friday, March 7, 2025 |
|
|
OrbusNeich Achieves Fourth Consecutive Year of Revenue Growth with Record High Revenue of US$164.1 Million and Net Profit of US$39.7 Million |
| OrbusNeich Medical Group Holdings Limited ('OrbusNeich' or the 'Group'; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention ('PCI') and percutaneous transluminal angioplasty ('PTA') procedures, today announced its annual results for the year ended December 31, 2024 (the 'Year'), reporting record-high revenue and healthy net profit despite the challenging business landscape. more info >> |
|
| Friday, August 16, 2024 |
|
|
OrbusNeich Records Net Profit of US$18.8 Million for the First Half of 2024 |
| OrbusNeich Medical Group Holdings Limited ('OrbusNeich' or the 'Group'; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention ('PCI') and percutaneous transluminal angioplasty ('PTA') procedures, today announced its interim results for the six months ended June 30, 2024 (the 'Reporting Period), with revenue and profit for the period attributable to owners of the Company maintained at US$78.9 million and US$18.8 million respectively despite various market challenges. more info >> |
|
| Wednesday, April 24, 2024 |
|
|
OrbusNeich's Joint Venture Kicks Off TricValve Clinical Trial in Mainland China |
| OrbusNeich Medical Group Holdings Limited announced today that the Group's joint venture OrbusNeich P+F Company Limited ("ON P&F") has commenced the clinical trial for the TricValve Transcatheter Bicaval Valve System ("TricValve"), to treat patients with hemodynamically relevant tricuspid insufficiency and caval reflux, on April 22, 2024 across Mainland China. more info >> |
|
| Thursday, March 7, 2024 |
|
|
OrbusNeich Achieves Record-High Revenue and Net Profit of US$154 Million and US$45.1 Million Respectively, Recommends Final Dividend Payment of HK10 cents per Share |
| OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures more info >> |
|
| Monday, November 27, 2023 |
|
|
OrbusNeich Acquires 84% Stake in Indonesian Distributor PT Revass for Approximately US$15 Million |
| OrbusNeich Medical Group Holdings Limited ("OrbusNeich", 6929.HK), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures more info >> |
|
| Thursday, November 23, 2023 |
|
|
OrbusNeich Adds Drug-eluting Balloons in Product Portfolio Through Acquisition of Eucatech AG |
| OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures more info >> |
|
| Thursday, August 17, 2023 |
|
|
OrbusNeich FY2023 Interim Net Profit Triples to US$25.2 Million, Total Revenue Increases by 18.2% to US$81.4 Million |
| OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, today announced its interim results for the six months ended 30 June 2023, reporting growth in both revenue and net profit. more info >> |
|
| Monday, May 8, 2023 |
|
|
OrbusNeich Kicks Off Clinical Study of Scoreflex TRIO, Completing China's First PCI Intervention Procedure with High-Pressure, Three-wire Scoring Balloon Dilatation Catheter |
| OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Formerra Announces Transportation Surcharge to Address Ongoing Freight and Logistics Market Pressures
Mar 26, 2026 04:00 HKT/SGT
|
|
|
Aleen Inc. Introduces Biomarker Data Layer in Personal Wellness Account
Mar 25, 2026 23:28 HKT/SGT
|
|
|
Hengrui Pharma Announces Strong 2025 Annual Results
Mar 25, 2026 23:15 HKT/SGT
|
|
|
Everbright Grand China Assets Recorded Revenue of RMB49.9 Million in 2025
Mar 25, 2026 22:39 HKT/SGT
|
|
|
Lithium Measurement MR-Technology Provider NanoNord Expands Business with DLE Leader ElectraLith, Following Danish State Visit to Australia
Mar 25, 2026 20:30 HKT/SGT
|
|
|
Adyton Reports 6.60g/t Au, 2.44% Cu and 39.8g/t Ag Within 164m @ 0.82g/t AuEq Including 53m at 1.60g/t AuEq Within 164m at 0.82g/t AuEq from the Northeastern Extension Target, Feni Island
Mar 25, 2026 19:29 HKT/SGT
|
|
|
Emperor Watch & Jewellery Limited Announces 2025 Annual Results
Mar 25, 2026 18:06 HKT/SGT
|
|
|
Kingsoft announces 2025 Annual and Fourth Quarter Results
Mar 25, 2026 18:06 HKT/SGT
|
|
|
New 2026 Office Bearers Announced for CropLife Asia
Mar 25, 2026 18:00 HKT/SGT
|
|
|
IGG 'Doomsday: Last Survivors' Achieves Record-High Monthly Gross Billing of HK$130 Million
Mar 25, 2026 17:40 HKT/SGT
|
|
|
Exito Media Concepts Announces the 31st Global Edition of the Cyber Security Summit Australia 2026 
Mar 25, 2026 17:18 HKT/SGT
|
|
|
Exito Media Concepts Announces the 33rd Global Edition of the BFSI IT Summit Australia 2026
Mar 25, 2026 16:58 HKT/SGT
|
|
|
GTJAI (1788.HK) Achieved Record-High Revenue in 2025 with Profitability Making a Leapfrog Improvement
Mar 25, 2026 16:44 HKT/SGT
|
|
|
Everest Medicines Enters into Asset Purchase Agreement for Etripamil Nasal Spray, Expanding Cardiovascular Footprint
Mar 25, 2026 16:34 HKT/SGT
|
|
|
Thailand Exhibition Association Unveils Transformative MICE Masterplan 2026-2027
Mar 25, 2026 16:26 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
